Citigroup Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00

Larimar Therapeutics (NASDAQ:LRMR) had its target price hoisted by Citigroup from $12.00 to $14.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 126.57% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Larimar Therapeutics in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Lifesci Capital upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $16.14.

Larimar Therapeutics Trading Up 67.5%

Shares of NASDAQ:LRMR traded up $2.49 during midday trading on Wednesday, reaching $6.18. 70,082,940 shares of the company were exchanged, compared to its average volume of 4,769,893. The stock has a market cap of $511.49 million, a PE ratio of -3.24 and a beta of 1.01. The business’s fifty day moving average is $3.44 and its two-hundred day moving average is $3.76. Larimar Therapeutics has a one year low of $1.61 and a one year high of $6.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LRMR. XTX Topco Ltd lifted its holdings in Larimar Therapeutics by 127.1% in the fourth quarter. XTX Topco Ltd now owns 118,938 shares of the company’s stock worth $453,000 after purchasing an additional 66,569 shares during the period. Quadrature Capital Ltd grew its holdings in Larimar Therapeutics by 195.4% during the fourth quarter. Quadrature Capital Ltd now owns 57,646 shares of the company’s stock valued at $220,000 after purchasing an additional 38,131 shares during the last quarter. Millennium Management LLC increased its holdings in Larimar Therapeutics by 7.2% in the 4th quarter. Millennium Management LLC now owns 5,206,364 shares of the company’s stock valued at $19,836,000 after buying an additional 349,533 shares during the period. Man Group plc bought a new position in shares of Larimar Therapeutics in the fourth quarter valued at approximately $149,000. Finally, Bridgeway Capital Management LLC grew its position in shares of Larimar Therapeutics by 42.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 111,216 shares of the company’s stock valued at $424,000 after purchasing an additional 33,000 shares during the period. Institutional investors own 91.92% of the company’s stock.

More Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia; Larimar reiterated plans to submit a BLA in June 2026 with topline open‑label data expected Q2 2026 and a potential U.S. launch in H1 2027 — this materially raises the drug’s regulatory and commercial prospects. Press release: Larimar Announces FDA Breakthrough Therapy Designation
• Positive Sentiment: Analyst support picked up: Wedbush reaffirmed an “outperform” rating and placed an $11 price target (roughly +85% from the pre-news level cited), which can validate upside expectations and attract momentum buyers. Benzinga
• Positive Sentiment: Lifesci Capital upgraded LRMR to a “strong-buy”, adding further buy-side signals that can support continued inflows from retail and institutional investors. Zacks.com
• Positive Sentiment: Unusual options activity: traders bought ~3,744 call contracts (≈+456% vs. typical daily call volume), indicating speculative bullish positioning that often accompanies rapid share-price rallies and can amplify short‑term volatility and buying pressure.
• Neutral Sentiment: Broad media coverage and explanatory articles explaining the FDA designation and share surge have increased visibility and may attract additional speculative interest. Investing.com: Larimar stock surges on FDA breakthrough status
• Neutral Sentiment: Multiple outlets summarized the move and drivers (MSN, AAII), which helps explain the rally to a wider audience but does not itself change fundamentals. MSN: Larimar surges on FDA breakthrough status

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.